Search

everythinglearnresearchcommunity

for

Search:↓

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

JAK inhibitors are effective and safe for treating severe alopecia areata.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.

EGFR inhibitors can cause unusual localized hair growth.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

Using minoxidil and tofacitinib together can effectively treat severe hair loss.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Erlotinib can cause excessive eyelash growth.

Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.

Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.

Nilotinib can cause keratosis pilaris, a skin condition.

Filgotinib completely reversed hair loss in a patient with rheumatoid arthritis and alopecia universalis.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Upadacitinib effectively treats pyoderma gangrenosum.

Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.